This test screens for 50 cancers — but whether Medicare and other health insurers will cover it hinges on FDA approval
Grail’s Galleri test looks for 50 cancers from a blood draw, but a major study failed to prove it could detect later-stage cancers.
We haven't written up this one. MarketWatch has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.